Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. - Seite 2

"We are delighted to announce our collaboration with the distinguished team at Mosaic to advance our AI-driven necroptosis cancer therapies. Mosaic is well-equipped to rapidly develop and refine this groundbreaking technology. Together, we expect to deliver significant advancements in the field of oncology with this technology." expressed Dr. Vuong Trieu, CEO of Oncotelic.

About Necroptosis Cancer Therapies

A recent approval of tumor infiltrating lymphocyte, or TIL cell therapy demonstrates how to manipulate patient immunity against cancer for lasting cure. However, TIL cell therapy is costly, time consuming and technologically challenging. Instead of driving TIL cells externally, Necroptosis Cancer Therapies drive innate TILs to the tumor. The key step is the induction of necrotic cell death and activation of death genes, exposing tumor-reactive antigens to initiate an immune response, activating antigen-presenting cells (APCs) to achieve large-scale antigen presentation, activating T-cells, inducing strong and sustained cytotoxic T lymphocyte responses, and ultimately triggering a TIL antitumor immune effect. Necroptosis Cancer Therapies can use Vascular Disrupting Agents (VDAs) in combination with Check-Point Inhibitors (CKIs) and other Immuno-Oncology (IO) agents to drive TIL cells to the tumor. Our VDAs can act as a component for the TIL/Necroptosis Cancer Therapies. The Necroptosis Cancer Therapies will be developed in conjunction with Artificial Intelligence (AI) technology using a list of proprietary death genes.

About Mosaic ImmunoEngineering, Inc.

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing cancer therapies for areas of high unmet medical need. Mosaic's management and board of directors' team has broad experience in bringing oncology and orphan drug products to the market with a combined experience including well over 30 FDA and worldwide product approvals. For additional information about Mosaic, please visit www.MosaicIE.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward-looking statements when we discuss Mosaic's future operations and its ability to successfully advance the product candidates; the nature, strategy and focus of Mosaic's business; and the development and commercial potential and potential benefits of any of Mosaic's product candidates. Mosaic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on Mosaic's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of these forward-looking statements could differ materially from those described in or implied by the statements in this press release, including the uncertainties of: entering into a definitive agreement with Oncotelic, obtaining shareholder approval for the transaction with Oncotelic, successfully completing due diligence under the binding term sheet, raising sufficient capital or grant funding to advance the underlying product candidates under the binding term sheet, which may not be available on favorable terms or at all; advancing the VDA technology into clinical trials, the clinical development and regulatory approval of product candidates under the binding term sheet, including potential delays in the commencement; enrollment and completion of clinical trials; The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risks discussed in Mosaic's filings with the Securities and Exchange Commission. Except as otherwise required by law, Mosaic disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether, as a result of new information, future events or circumstances or otherwise.